Gilead Sciences Unveils Game-Changing PrEP Strategy—Inside the Yeztugo Breakthrough!

Gilead Sciences’ third quarter of 2025 results demonstrate mixed performance across the company’s diverse portfolio, characterized by both significant growth in certain segments and challenges in others. The HIV therapy segment remains a stronghold for Gilead, seeing expanding revenues with products like Biktarvy and Descovy demonstrating year-over-year growth of 6% and 20%, respectively. Notably, Biktarvy achieved a record U.S. market share, highlighting robust demand driven by the company’s commercial execution. Gilead also reported 5% year-over-year growth expectations for its HIV segment, despite a $900 million impact from the Medicare Part D redesign. The introduction of Yeztugo, a new entrant in the HIV prevention market, showed promising signs by achieving $39 million in sales and 75% payer coverage ahead of schedule. This product’s early success indicates strong market uptake potential, given the growing awareness and access within the prevention market.